BACKGROUND: Systolic heart failure (HF) is a complex systemic syndrome that can result from a wide variety of clinical conditions and gene mutations. Despite phenotypic similarities, characterized by ventricular dilatation and reduced contractility, the extent of common and divergent gene expression between different forms of HF remains a matter of intense debate. METHODS AND RESULTS: Using a meta-analysis of 28 experimental (mouse, rat, dog) and human HF microarray studies, we demonstrate that gene expression changes are characterized by a coordinated and reciprocal regulation of major metabolic and signaling pathways. In response to a wide variety of stressors in animal models of HF, including ischemia, pressure overload, tachypacing, chronic isoproterenol infusion, Chagas disease, and transgenic mouse models, major metabolic pathways are invariably downregulated, whereas cell signaling pathways are upregulated. In contrast to this uniform transcriptional pattern that recapitulates a fetal gene expression program in experimental animal models of HF, human HF microarray studies displayed a greater heterogeneity, with some studies even showing upregulation of metabolic and downregulation of signaling pathways in end-stage human hearts. These discrepant results between animal and human studies are due to a number of factors, prominently cardiac disease and variable exposure to cold cardioplegic solution in nonfailing human samples, which can downregulate transcripts involved in oxidative phosphorylation (OXPHOS), thus mimicking gene expression patterns observed in failing samples. Additionally, β-blockers and ACE inhibitor use in end-stage human HF was associated with higher levels of myocardial OXPHOS transcripts, thus partially reversing the fetal gene expression pattern. In human failing samples, downregulation of metabolism was associated with hemodynamic markers of disease severity. CONCLUSIONS: Irrespective of the etiology, gene expression in failing myocardium is characterized by downregulation of metabolic transcripts and concomitant upregulation of cell signaling pathways. Gene expression changes along this metabolic-signaling axis in mammalian myocardium are a consistent feature in the heterogeneous transcriptional response observed in phenotypically similar models of HF.
BACKGROUND: Systolic heart failure (HF) is a complex systemic syndrome that can result from a wide variety of clinical conditions and gene mutations. Despite phenotypic similarities, characterized by ventricular dilatation and reduced contractility, the extent of common and divergent gene expression between different forms of HF remains a matter of intense debate. METHODS AND RESULTS: Using a meta-analysis of 28 experimental (mouse, rat, dog) and human HF microarray studies, we demonstrate that gene expression changes are characterized by a coordinated and reciprocal regulation of major metabolic and signaling pathways. In response to a wide variety of stressors in animal models of HF, including ischemia, pressure overload, tachypacing, chronic isoproterenol infusion, Chagas disease, and transgenicmouse models, major metabolic pathways are invariably downregulated, whereas cell signaling pathways are upregulated. In contrast to this uniform transcriptional pattern that recapitulates a fetal gene expression program in experimental animal models of HF, human HF microarray studies displayed a greater heterogeneity, with some studies even showing upregulation of metabolic and downregulation of signaling pathways in end-stage human hearts. These discrepant results between animal and human studies are due to a number of factors, prominently cardiac disease and variable exposure to cold cardioplegic solution in nonfailing human samples, which can downregulate transcripts involved in oxidative phosphorylation (OXPHOS), thus mimicking gene expression patterns observed in failing samples. Additionally, β-blockers and ACE inhibitor use in end-stage human HF was associated with higher levels of myocardial OXPHOS transcripts, thus partially reversing the fetal gene expression pattern. In human failing samples, downregulation of metabolism was associated with hemodynamic markers of disease severity. CONCLUSIONS: Irrespective of the etiology, gene expression in failing myocardium is characterized by downregulation of metabolic transcripts and concomitant upregulation of cell signaling pathways. Gene expression changes along this metabolic-signaling axis in mammalian myocardium are a consistent feature in the heterogeneous transcriptional response observed in phenotypically similar models of HF.
Authors: L W Stanton; L J Garrard; D Damm; B L Garrick; A Lam; A M Kapoun; Q Zheng; A A Protter; G F Schreiner; R T White Journal: Circ Res Date: 2000-05-12 Impact factor: 17.367
Authors: Roger A Wagner; Raymond Tabibiazar; Jennifer Powers; Daniel Bernstein; Thomas Quertermous Journal: J Mol Cell Cardiol Date: 2004-12 Impact factor: 5.000
Authors: Sarah Crunkhorn; Farrell Dearie; Christos Mantzoros; Hiral Gami; Wagner S da Silva; Daniel Espinoza; Ryan Faucette; Kristen Barry; Antonio C Bianco; Mary Elizabeth Patti Journal: J Biol Chem Date: 2007-04-06 Impact factor: 5.157
Authors: Claes C Strøm; Mogens Kruhøffer; Steen Knudsen; Frank Stensgaard-Hansen; Thomas E N Jonassen; Torben F Orntoft; Stig Haunsø; Søren P Sheikh Journal: Comp Funct Genomics Date: 2004
Authors: Yan Ru Su; Manuel Chiusa; Evan Brittain; Anna R Hemnes; Tarek S Absi; Chee Chew Lim; Thomas G Di Salvo Journal: Pulm Circ Date: 2015-09 Impact factor: 3.017
Authors: Thomas G Di Salvo; Yan Guo; Yan Ru Su; Travis Clark; Evan Brittain; Tarek Absi; Simon Maltais; Anna Hemnes Journal: Pulm Circ Date: 2015-03 Impact factor: 3.017
Authors: Scot J Matkovich; Belal Al Khiami; Igor R Efimov; Sarah Evans; Justin Vader; Ashwin Jain; Bernard H Brownstein; Richard S Hotchkiss; Douglas L Mann Journal: Crit Care Med Date: 2017-03 Impact factor: 7.598
Authors: Kathryn C Chatfield; Genevieve C Sparagna; Carmen C Sucharov; Shelley D Miyamoto; Jonathan E Grudis; Rebecca D Sobus; Jamie Hijmans; Brian L Stauffer Journal: J Mol Cell Cardiol Date: 2014-06-14 Impact factor: 5.000